PapersTrialsTopicsCompoundsCountriesStakeholdersPeopleCoursesEvents
Browse all papers

Latest papers

Long-term efficacy of psilocybin with adjunct psychotherapy in treatment-resistant depressionPsilocybin · Treatment-resistant depressionDrug-drug interactions between psychiatric medications and MDMA or psilocybinMDMA & psilocybin · SafetyAn international mega-analysis of psychedelic drug effects on brain circuit functionCross-compound · NeuroimagingEsketamine in treatment-resistant depression with and without comorbid borderline personalityEsketamine · Treatment-resistant depression

Featured

Road to Access

Science, regulation, and economics on the path to patient access.

01Evidence02Approval03Reimbursement04Delivery05Access—Big Picture
Start the journey
ResultsCompare outcome data across trials and publications.Research SnapshotOne-page overview of trials, participants, papers, and research networks.Clinical GuidelinesTrial-anchored manuals and protocol guidance with competency mapping.Research recapsMonthly evidence summaries with key takeaways.Map of researchLandscape view of trials, compounds, and outcomes.NewsletterWeekly or daily updates on trials, publications, analysis, and more.Research GroupsWorldwide map of psychedelic research centres by region.Research NetworkInteractive co-authorship map of psychedelic researchers.Top papersFind needles in the haystack of psychedelic research per topic.
AskBeta
Pricing
Back to journals
Academic Journal

Movement Disorders Clinical Practice

1 Papers Indexed in Blossom

Data updated June 16, 2026

Research Footprint

Movement Disorders Clinical Practice has 1 tracked paper indexed in Blossom (2015) from 3 authors, most often covering Ayahuasca, across Depressive Disorders and Neurocognitive Disorders.

Published Papers

Open Accessmeta

Banisteriopsis caapi, a Forgotten Potential Therapy for Parkinson’s Disease?

The paper reviews early 1920s–30s clinical trials and the pharmacology of Banisteriopsis caapi and its harmala alkaloids (notably harmine), and argues that—despite historical abandonment—harmine merits reevaluation as a potential rapidly acting anti‑Parkinsonian agent.

Published
October 6, 2015
Journal
Movement Disorders Clinical Practice
Authors
Bernschneider‐Reif, S., Poewe, W., Lees, A.

Quick Facts

Papers Indexed
1
h-Index
42
Open Access
No
Publisher
Wiley
Country
United States
Website
Visit

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.